Osteoporosis is a progressive condition where bone density decreases, increasing fracture risk. It often develops silently with no early symptoms. Treatment aims to slow bone loss, maintain density, and reduce fracture risk, especially in high-risk sites (hip, spine, wrist).
Calcium and vitamin D supplementation form the foundation: calcium 1,000–1,200 mg daily (dietary or supplement) and vitamin D 800–2,000 IU daily, adjusted based on blood levels. Weight-bearing and resistance exercise (walking, strength training) stimulates bone formation and is essential. Bisphosphonates (alendronate, risedronate, ibandronate) are first-line pharmacotherapy; they slow bone loss and reduce fracture risk. Denosumab, a monoclonal antibody blocking RANKL, is equally effective and used if bisphosphonates are contraindicated or poorly tolerated. Hormone-replacement therapy (HRT) with oestrogen is effective in postmenopausal women but carries risks; it is now reserved for women with severe symptoms or high fracture risk. Selective oestrogen-receptor modulators (SERMs, e.g. raloxifene) mimic oestrogen benefits without some risks. Teriparatide (PTH analogue) stimulates bone formation and is reserved for severe cases.
Plant-derived compounds, including isoflavones from soy, have modest evidence for bone health. Herbal supplements (red clover, black cohosh for menopausal symptoms) are used but lack strong evidence. Magnesium and trace minerals (boron, zinc) support bone metabolism if deficient. Phytoestrogens in a plant-rich diet may help. Acupuncture and traditional Chinese medicine approaches are used but lack robust evidence. Adequate protein intake (1–1.2 g/kg body weight) is important for bone quality.
Regenerative approaches for osteoporosis are in early stages. Bone-marrow-derived mesenchymal stem cells show promise in preclinical and early clinical studies for promoting bone formation and restoring density. Parathyroid hormone-related peptide (PTHrP) and other biologics are under investigation to stimulate osteoblast activity. These remain largely experimental outside clinical trials. Candidacy would depend on severe osteoporosis unresponsive to conventional therapy. Learn more at emerging regenerative options for bone and research participation criteria.
| Option | Type | Evidence | Indicative cost | Invasiveness | Recovery |
|---|---|---|---|---|---|
| Calcium & vitamin D supplementation | Standard | Strong | €10–30/month | Low | Ongoing; benefits accrue over years |
| Weight-bearing & resistance exercise | Standard | Strong | €0–100/month | Low | Ongoing; benefits in 6–12 months |
| Alendronate (bisphosphonate) | Standard | Strong | €20–50/month | Low | Ongoing; requires proper administration |
| Denosumab (RANKL inhibitor) | Standard | Strong | €100–200 per injection | Medium | Ongoing; injection twice yearly |
| Hormone-replacement therapy (HRT) | Standard | Moderate | €50–150/month | Low | Ongoing; risks/benefits discussed with provider |
| Teriparatide (PTH analogue) | Standard | Strong | €300–500/month | Medium | Ongoing; daily injection |
| Soy isoflavones or phytoestrogens | Alternative | Limited | €20–50/month | Low | Ongoing; 3–6 months trial |
| Stem-cell bone-formation therapy | Regenerative | Investigational | €5,000–15,000 | Medium | Few weeks; early-stage research |
Initial screening is recommended at age 65 for women and 70 for men; earlier if risk factors exist (family history, corticosteroid use, low BMI). After diagnosis, scans are typically repeated every 1–2 years during treatment to assess response. Intervals vary based on baseline scores and treatment type.
Bisphosphonates are generally safe; most people tolerate them well. Rare side effects include jaw necrosis (very rare, especially with oral forms) and atypical fractures (extremely uncommon). Regular dental care and adequate calcium/vitamin D intake minimise risks. Discuss duration with your doctor; some recommend "drug holidays" after 5 years, though evidence is mixed.
Lifestyle (exercise, calcium, vitamin D, smoking cessation) slows loss and improves bone quality but typically cannot reverse established low density. Medications combined with lifestyle changes are most effective. Early intervention—before significant bone loss—yields the best outcomes.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Educational overview of treatment options; not medical advice. Standard treatments reflect mainstream guidance; regenerative/stem-cell uses are largely investigational. Reviewed by the StemCellAtlas editorial team.
Médecine régénérative certifiée GMP au cœur de l'UE — à partir de 3 000–8 000 €, une fraction des prix américains ou allemands. Protocoles personnalisés pour patients de plus de 50 pays.
Évaluation médicale gratuite